DIAZOLIN FOR CHILDREN
UkraineThe drug is used for the prevention and treatment of seasonal allergic rhinitis, pollen allergy, urticaria, as well as food and drug allergies. It is also prescribed for dermatoses accompanied by skin itching (e.g., eczema or neurodermatitis).
Frequently asked questions
How should the drug be prepared and taken correctly?
Add 100 ml of freshly boiled warm water (40–50 °C) to the granule vial and stir for 10 minutes. The suspension should be shaken before each dose. The medicine should be taken after meals, using the graduated cup provided in the package.
What dosage of Diazolin for children should be used?
The dosage depends on the child's age: children 2–3 years old — 2.5 ml; 4–6 years old — 5 ml; 7–10 years old — 7.5 ml. It should be taken 2–3 times a day. The course of treatment usually lasts 5–7 days.
Who should not take this drug?
The drug is contraindicated in cases of individual hypersensitivity to the components, gastric and duodenal ulcers, inflammatory diseases of the digestive tract, prostatic hyperplasia, angle-closure glaucoma, pylorostenosis, epilepsy, and cardiac rhythm disturbances.
What side effects may occur?
Possible dyspeptic phenomena (heartburn, nausea, abdominal pain), dizziness, drowsiness, increased fatigue, tremor, anxiety, dry mouth, or urinary disturbances. Occasionally, paradoxical reactions such as irritability or increased excitement may occur.
Can this product be combined with other medicines?
The drug may enhance the effect of other agents that depress the central nervous system.
What should be noted during use?
Since the drug contains sugar, if you have an intolerance, you must consult a doctor. Caution should also be exercised in cases of hepatic or renal impairment, as a dose adjustment may be required.
Instructions for use
INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT DIAZOLINE FOR CHILDREN
Composition:
Active substance: mebhydrolin;
1 vial contains mebhydrolin (diazolin) 0.6 g;
5 ml of ready-made suspension contains mebhydrolin (diazolin) 0.03 g (30.0 mg);
Excipients: sugar, glycyrrhizin, povidone, sorbic acid.
Pharmaceutical form. Granules for oral suspension.
Main physico-chemical properties: granules from light cream to cream in color, with a specific odor.
Pharmacotherapeutic group. Antihistamines for systemic use.
ATC code R06AX15.
Pharmacological properties.
Pharmacodynamics. Mebhydrolin belongs to antihistamine agents and is an H1-histamine receptor blocker. Mebhydrolin reduces the spasmogenic effect of histamine on smooth muscles of bronchi and intestines, and also affects vascular permeability. It does not have pronounced sedative or hypnotic effects.
Pharmacokinetics. Rapidly absorbed from the gastrointestinal tract. Bioavailability ranges between 40–60%. Therapeutic effect develops within 15–30 minutes, with maximum effect observed within 1–2 hours. The drug practically does not penetrate the blood-brain barrier, is metabolized in the liver via methylation, induces liver enzymes, and is excreted from the body by the kidneys.
Clinical characteristics.
Indications. Prevention and treatment of seasonal allergic rhinitis, hay fever, urticaria, food and drug allergies, and dermatoses accompanied by skin itching (eczema, neurodermatitis).
Contraindications. Individual hypersensitivity to the drug. Peptic ulcer of the stomach and duodenum, other inflammatory diseases of the gastrointestinal tract, prostatic hyperplasia, closed-angle glaucoma, pylorostenosis, epilepsy, cardiac arrhythmias.
Interaction with other medicinal products and other forms of interaction. The drug potentiates the effect of medicinal products that depress the central nervous system.
Special precautions for use.
When treating young children, it is necessary to strictly adhere to dosage recommendations (psychomotor excitation is possible).
The drug should be used with caution in patients with hepatic or renal insufficiency (dose adjustment and dosing intervals may be required).
The product contains sugar. If the patient has a known intolerance to certain sugars, medical advice should be sought before taking this medicinal product.
Use during pregnancy or breastfeeding. The drug is intended for children aged 2 to 10 years.
Ability to affect reaction rate when driving or operating machinery. The drug is intended for children aged 2 to 10 years.
Method of Administration and Dosage
Before use, add 100 mL of freshly boiled warm water at a temperature between 40 °C and 50 °C to the vial containing granules, and mix for 10 minutes; after that, the suspension is ready for use. Measure the suspension dose using the graduated cup provided in the package.
For children aged 2–3 years, the dose is 2.5 mL; for children aged 4–6 years, 5 mL; for children aged 7–10 years, 7.5 mL, administered 2–3 times daily after meals. The duration of treatment is 5–7 days. The suspension must be shaken well before administration.
Children. The drug is intended for children aged 2 to 10 years.
Overdose. In case of overdose, adverse reactions listed in the relevant section occur more frequently. In such cases, discontinue the drug, administer symptomatic therapy, and, if necessary, carry out general detoxification measures (gastric lavage, forced diuresis).
Side effects.
Gastrointestinal tract: dyspeptic symptoms (heartburn, nausea, epigastric pain).
Central nervous system: dizziness, paresthesia, increased fatigue, drowsiness, blurred vision, tremor, slowed reaction time, anxiety (at night).
Other: dry mouth, urinary disturbances, allergic reactions; granulocytopenia and agranulocytosis may occur very rarely.
Paradoxical reactions such as increased excitability, irritability, tremor, and sleep disturbances may occasionally occur.
Shelf life. 3 years. The shelf life of the suspension is 7 days.
Storage conditions. Store at a temperature not exceeding 25 °C in the original packaging.
Keep out of reach of children.
Packaging. 9 g in a bottle with a dosing cup in a carton.
Prescription status. Over-the-counter.
Manufacturer.
Limited Liability Company "Research Plant "GNCLC".
Limited Liability Company "Pharmaceutical Company "Zdorovye".
Manufacturer's address and place of business.
Ukraine, 61057, Kharkiv region, city of Kharkiv, Vorobiova Street, building 8.
(Limited Liability Company "Research Plant "GNCLC")
Ukraine, 61013, Kharkiv region, city of Kharkiv, Shevchenka Street, building 22.
(Limited Liability Company "Pharmaceutical Company "Zdorovye")
The original data is available in the language of the country of manufacture.
Data source: State Register of Medicinal Products of Ukraine
Data last verified: August 13, 2026